Tipharco Pharmaceutical JSC 2024 AR2
The report highlights Tipharco Pharmaceutical Joint Stock Company's operational and financial performance for the fiscal year 2024, alongside its sustainable development initiatives. Despite market challenges, the company maintained stable net revenue of VND 364.1 billion and expanded its ETC channel. Tipharco officially exported its products to Cambodia for the first time and received WHO-GMP compliance approval for its manufacturing lines. On the sustainability front, the company implemented energy-efficiency measures, managed waste and wastewater systematically, and actively engaged in community health programs, including donating medicine to flood-affected areas.
Company: Tipharco Pharmaceutical JSC
Sector: Health Care
Country: Vietnam
Year: 2024
Type: AR2
Pages: 57
Tipharco Pharmaceutical JSC
Annual Report
The report highlights Tipharco Pharmaceutical Joint Stock Company's operational and financial performance for the fiscal year 2024, alongside its sustainable development initiatives. Despite market challenges, the company maintained stable net revenue of VND 364.1 billion and expanded its ETC channel. Tipharco officially exported its products to Cambodia for the first time and received WHO-GMP compliance approval for its manufacturing lines. On the sustainability front, the company implemented energy-efficiency measures, managed waste and wastewater systematically, and actively engaged in community health programs, including donating medicine to flood-affected areas.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 18, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Women in Management
Employees